An interventional study of Methimazole and Methimazole in Graves Disease, sponsored by Mashhad University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-03-22.
Sponsored by Mashhad University of Medical Sciences · Not applicable, Interventional, and Treatment
Iodine therapy is the best treatment for graves disease.Most patients receive methimozale prior to radio-iodine treatment. This may decrease treatment response to iodine therapy.
Some physicians advice to discontinue methimazole 3 days before radioiodine therapy and others prefer longer off - methimazole period which bothers most patients. This study aimed to evaluate optimum time for methimazole discontinuation in graves disease.
150 studies on the registry are indexed under Graves Disease; 53 are open to participants now.
This study's enrollment of 150 is above the median of 60 across 92 interventional studies indexed under Graves Disease.
Browse Graves Disease studies →Mashhad University of Medical Sciences is the lead sponsor of 90 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This group will be advised to discontinue methimazole 24-48 hour before iodine therapy
Drug: Methimazole
methimazole stopped 48-72 hour before radioiodine therapy
Drug: Methimazole
Drug: Methimazole
Methimazole was stopped 24-48 before radio-iodine therapy
methimazole discontinued 49-72 hours before radioiodine treatment
methimazole discontinued 73-168 hours before radio-iodine treatment
thyroid function tests over one year after radioiodine therapy
thyroid function test may change over one year . In order to consider the patients as cured ,thyroid function tests should reveal hypothyroidism or euthyroidism . In order to rule out temporary hypothyroidism the tests should be repeated after 6 months of radioiodine therapy.
Time frame: months 1 , 3 ,6,9,12
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mashhad University of Medical Sciences